FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

🥺🥺🥺

Yeeaah 👍👍👍

*** durch finanz.trends (ohne den Punkt) ersetzen

https://www.finanztrends.de/biotech-aktien-der-taegliche-biotech-puls-2/

gibts auch news auf deutsch?warum absturz

FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results http://www.globenewswire.com/news-release/2021/03/01/2184671/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application

FibroGen EPS misses by $0.38, misses on revenue https://seekingalpha.com/news/3667889 • FibroGen (NASDAQ:FGEN): Q4 GAAP EPS of -$0.64 misses by $0.38. • Revenue of $64.99M (+715.4% Y/Y) misses by $35.83M. • Shares -17.3%.

BRIEF-FibroGen Inc Entered Into A Supply Agreement With Astellas Pharma Europe Ltd On Jan. 13 https://pub.webull.com/us/news-html/b6d596de08104c34ac7963f93f2045eb.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en https://m.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/FIBROGEN-INC-Entry-into-a-Material-Definitive-Agreement-form-8-K-32286087/

https://seekingalpha.com/article/4396152-fibrogen-roxadustats-u-s-approval-2020-china-sales-and-outsized-growth

FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 https://www.globenewswire.com/news-release/2020/12/22/2149257/0/en/FibroGen-Advances-Phase-3-Clinical-Development-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-with-Initiation-of-ZEPHYRUS-2.html

Fibrogen falls in post-market ahead of FDA decision https://seekingalpha.com/news/3645986-fibrogen-falls-in-post-market-ahead-of-fda-decision FibroGen Provides Regulatory Update on Roxadustat https://www.globenewswire.com/news-release/2020/12/18/2148127/0/en/FibroGen-Provides-Regulatory-Update-on-Roxadustat.html ...today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) by three months. The updated Prescription Drug User Fee Act (PDUFA) action date is March 20, 2021.  ...

FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication https://www.nasdaq.com/articles/fibrogens-fgen-evrenzo-approved-in-japan-for-another-indication-2020-11-30 FibroGen, Inc. FGEN, along with partner Astellas Pharma Inc. announced that it has received a second marketing approval for Evrenzo (roxadustat in Japan. The Japanese regulatory authority has now given a nod to roxadustat for the treatment of anemia of chronic kidney disease (“CKD” in adult patients who are not on dialysis. Notably, roxadustat was approved for the treatment of anemia caused by CKD in dialysis-dependent patients in September 2019. ...

http://www.globenewswire.com/news-release/2020/11/27/2135245/0/en/Astellas-Receives-Approval-of-EVRENZO-roxadustat-in-Japan-for-the-Treatment-of-Anemia-of-Chronic-Kidney-Disease-in-Adult-Patients-Not-on-Dialysis.html

FibroGen Reports Third Quarter 2020 Financial Results https://www.globenewswire.com/news-release/2020/11/05/2121451/0/en/FibroGen-Reports-Third-Quarter-2020-Financial-Results.html - Strong Third Quarter China Roxadustat Net Sales of $22.7 Million - ...

https://pub.webull.com/us/news-html/2ed53ac64a2d4c70a7abbc5cb8a22fbf.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en&theme=1 FibroGen Inc (NASDAQ:FGEN) is a total spec and earnings won't matter, said Cramer. He likes the idea as long as investors put the stock in the total speculative column.

https://www.globenewswire.com/news-release/2020/10/22/2112965/0/en/FibroGen-Presents-Late-Breaker-Abstract-Results-on-Associations-between-Hemoglobin-Levels-and-Cardiovascular-Outcomes-in-Roxadustat-Treated-Patients-with-Anemia-of-Chronic-Kidney-D.html